Home > Newsletters > Washington Drug Letter > Merck Hit With Complete Response Letter on Potential Sarcoma Drug
Washington Drug Letter
June 11, 2012 | Vol. 44 No. 24
Merck Hit With Complete Response Letter on Potential Sarcoma Drug
The FDA has handed Merck a complete response letter on Taltorvic, a potential maintenance treatment for metastatic soft-tissue and bone sarcomas, calling for additional clinical trials to assess safety and efficacy.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.